Thematische Bibliographien / Menopause Hormone therapy

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Bücher
Buchteile
Konferenzberichte
Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Menopause Hormone therapy“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 31. Januar 2023

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Menopause Hormone therapy" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Menopause Hormone therapy"

Pearce, Jane, Keith Hawton und Fiona Blake. „Psychological and Sexual Symptoms Associated with the Menopause and the Effects of Hormone Replacement Therapy“. British Journal of Psychiatry 167, Nr. 2 (August 1995): 163–73. http://dx.doi.org/10.1192/bjp.167.2.163.

Der volle Inhalt der Quelle

Annotation:

BackgroundThere is considerable inconsistency in the results of studies of the psychological and sexual sequelae of the menopause and their treatment.MethodA search of the literature on Medline was made of studies of psychological symptoms in women who were either naturally or surgically menopausal or who were receiving hormone replacement therapy for menopausal symptoms.ResultsThere is evidence of a small increase in psychological morbidity (not usually amounting to psychiatric disorder) preceding the natural menopause and following the surgical menopause. Psychosocial as well as hormonal factors are relevant. While the response of psychosocial symptoms to hormone replacement therapy with oestrogens is variable and most marked in the surgical menopause, in some studies the effect is little greater than that for placebo. Where sexual symptoms are present, there is more consistent evidence that hormone replacement therapy is effective.ConclusionsIn the light of the available evidence, the current use of hormone replacement therapy to treat psychological symptoms detected at the time of (but not necessarily therefore due to) the natural menopause must be questioned. It does appear that oestrogen therapy ameliorates psychological symptoms after surgical menopause.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Hernández, Víctor Manuel Vargas. „Long-Term Consequences of Menopause Victor manuel vargas hernandez Academic of the Mexican Academy of Surgery Secretary of the Mexican Association for the study of Climacteric“. Obstetrics Gynecology and Reproductive Sciences 4, Nr. 3 (14.12.2020): 01–06. http://dx.doi.org/10.31579/2578-8965/094.

Der volle Inhalt der Quelle

Annotation:

The dramatic changes in sex hormone levels that occur during the transition to menopause and beyond are responsible for the long-term consequences, which are of primary importance to healthy aging in women. Sex hormones have a vital physiological role in maintaining the health and normal functioning of various organs; like bone, heart and brain. Disease activity is highly dependent on estrogen exposure; cardiovascular and musculoskeletal disorders frequently occur during postmenopause. Even cognitive decline is related to hypoestrogenism during the menopausal transition. Several lines of evidence indicate that the presence, duration and severity of menopausal vasomotor symptoms, especially hot flashes, not only have an impact on quality of life, but are biomarkers of increased risk of chronic conditions, which require prevention strategies, including menopausal hormone therapy. Nutrition, exercise, and other lifestyle measures, use of appropriate hormonal treatments in symptomatic women during the "window" of opportunity (under 60 years or within 10 years after menopause) can significantly counteract the process of aging of the female body. Meanwhile an individualized menopausal hormone therapy helps postmenopausal women overcome the burden of symptoms, including those related to Genitourinary Menopause Syndrome.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Romanenko, T. H., G. M. Zhaloba und N. V. Yesyp. „Menopause hormone therapy (Literature review)“. HEALTH OF WOMAN, Nr. 6(142) (29.07.2019): 87–91. http://dx.doi.org/10.15574/hw.2019.142.87.

Der volle Inhalt der Quelle

Annotation:

Practitioners in the fields of obstetrics and gynecology get used to look at the women’s health from the point of view of maintaining her reproductive potential and assistance in its fulfillment. Less attention is paid to the problem of reproductive function`s descent. Common changes during the menopausal transition were out of specialists` focus and women were left with no choice but to deal with those problems on their own. Nevertheless, global tendency of population ageing and growing awareness about the importance of professional and cultural activities of these women makes it important to deepen the knowledge of this subject and find out effective therapeutical methods for the liquidation of pathological manifestations of menopausal transition and improving life quality. Menopause hormone therapy received strong evidence to prove its effectiveness. However, specialists often underestimate or overestimate its potential in several clinical cases. Consequently, information about this method, precautions and contraindications should be well known for doctors and explained to their patients. Key words: perimenopause, climacteric syndrome, menopause hormone therapy, urogenital atrophy, osteoporosis, cardiovascular diseases, venous thromboembolism.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Noble, Nikki. „Hormone replacement therapy: update and practical prescribing“. Practice Nursing 32, Nr. 4 (02.04.2021): 148–56. http://dx.doi.org/10.12968/pnur.2021.32.4.148.

Der volle Inhalt der Quelle

Annotation:

Peri-menopause and menopause are a normal part of ageing. Nikki Noble gives an overview of hormone replacement therapy and practical prescribing tips Menopause is a physiological event of ovarian failure due to a loss of ovarian follicular activity. This leads to a lack of oestrogen, resulting in the cessation of menstruation and loss of reproductive function. This article discusses the symptoms of menopause and treatment with hormone replacement therapy. This includes practical prescribing, side effects and long-term benefits and risks. The current shortages of hormone replacement therapy are also addressed. The aim of this article is to enable health professionals to define menopause and gain an understanding of the symptoms associated with it. After reading this article you should be able to: describe when peri-menopause and menopause occur, describe the common symptoms that may be experienced during peri-menopause and menopause, understand of the hormones used in hormone replacement therapy, and understand the practical prescribing of hormone replacement therapy and the benefits, risks, contraindications and side-effects.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Noble, Nikki. „Hormone replacement therapy: update and practical prescribing“. Journal of Prescribing Practice 2, Nr. 2 (02.02.2020): 91–97. http://dx.doi.org/10.12968/jprp.2020.2.2.91.

Der volle Inhalt der Quelle

Annotation:

Menopause is a physiological event of ovarian failure due to a loss of ovarian follicular activity. This leads to a lack of oestrogen, resulting in the cessation of menstruation and loss of reproductive function. This article discusses the symptoms of menopause and treatment with hormone replacement therapy. This includes practical prescribing, side effects and long term benefits and risks. The current shortages of hormone replacement therapy are also addressed. The aim of this article is to enable healthcare professionals to define menopause and gain an understanding of the symptoms associated with it. After reading this article you should be able to: describe when peri-menopause and menopause occur, describe the common symptoms that may be experienced during peri-menopause and menopause, understand of the hormones used in hormone replacement therapy, and understand the practical prescribing of hormone replacement therapy and the benefits, risks, contraindications and side-effects.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Watt, Fiona E. „Hand osteoarthritis, menopause and menopausal hormone therapy“. Maturitas 83 (Januar 2016): 13–18. http://dx.doi.org/10.1016/j.maturitas.2015.09.007.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Topo, Paivi, und Elina Hemminki. „Is menopause withering away?“ Journal of Biosocial Science 27, Nr. 3 (Juli 1995): 267–76. http://dx.doi.org/10.1017/s0021932000022793.

Der volle Inhalt der Quelle

Annotation:

SummaryMenopause (cessation of menstruction) and the period surrounding it (climacterium) are often defined retrospectively by asking a woman the date of her last menstrual period (LMP). Based on a survey of 2000 women aged 45–64 in 1989 in Finland, this study examines (1) the relation between these definitions and women's own definitions of their climacteric status and of the cessation of menstruction and (2) the effect of menopausal and postmeno pausal hormone therapy and hysterectomy on the definition of menopause and climacterium. Agreement of the woman's own definition of her climacteric status and interval since LMP was 25% among current hormone users, 41% among hysterectomised women and 64% among those who were neither currently using hormones nor had been hysterectomised. Current hormone users defined the climacteric phase as longer than their LMP suggested. Current hormone use and hysterectomy had little effect on reported final cessation of menstrual periods. It is concluded that hysterectomy and hormone therapy shape women's thinking about the end of reproductive life, blur the concepts of menopause and postmenopause and confuse the measurement of age at menopause.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Smail, Linda, Ghufran A. Jassim und Khawla I. Sharaf. „Emirati Women’s Knowledge about the Menopause and Menopausal Hormone Therapy“. International Journal of Environmental Research and Public Health 17, Nr. 13 (06.07.2020): 4875. http://dx.doi.org/10.3390/ijerph17134875.

Der volle Inhalt der Quelle

Annotation:

The aim of this study was to investigate the knowledge of Emirati women aged 30–64 about menopause, menopausal hormone therapy (MHT), and their associated health risks, and additionally, to determine the relationships between Emirati women’s knowledge about menopause and their sociodemographic and reproductive characteristics. A community-based cross-sectional study was conducted of 497 Emirati women visiting five primary healthcare centers in Dubai. Data were collected using a questionnaire composed of sociodemographic and reproductive characteristics, menopause knowledge scale (MKS), and menopause symptoms knowledge and MHT practice. The mean menopause symptoms knowledge percentage was 41%, with a standard deviation of 21%. There were significant differences in the mean knowledge percentage among categories of education level (p < 0.001) and employment (p = 0.003). No significant differences in the knowledge percentages were found among categories of menopausal status. “Pregnancy cannot occur after menopause” was the statement with the highest knowledge percentage (83.3%), while the lowest knowledge percentages were “risk of cardiovascular diseases increases with menopause’’ (23.1%), “MHT increases risk of breast cancer’’ (22.1%), and “MHT decreases risk of colon cancer’’ (13.9%). The knowledge of Emirati women about menopause, MHT, and related heart diseases was very low; therefore, an education campaign about menopause and MHT risks is needed to improve their knowledge for better coping with the symptoms.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Anagnostis, Ellena A. „Menopausal Hormone Therapy (MHT)“. Journal of Pharmacy Practice 25, Nr. 3 (01.05.2012): 324–30. http://dx.doi.org/10.1177/0897190012442064.

Der volle Inhalt der Quelle

Annotation:

The perceptions of menopausal hormone therapy (MHT) have evolved considerably. Observational studies suggested that MHT could relieve vasomotor symptoms and prevent coronary heart disease (CHD). However, randomized controlled trials later showed no reduction in CHD and an increased risk of stroke. Subsequent analyses of these trials have shown that in women younger and closer to menopause, the risks associated with MHT may not be as great as originally thought. Several organizations, including the North American Menopause Society, the International Menopause Society, and the Endocrine Society, have published guidelines and statements that help health care providers translate the research findings into clinical practice. A common theme from these organizations is the need for health care providers to tailor information to their patients so they may make informed treatment decisions (especially considering the media attention MHT has received). It is particularly important to individualize therapy, considering patients’ risk factors for atherosclerotic disease, venous thromboembolic disease, osteoporosis, and breast cancer. Ongoing research in women younger than those in prior trials is evaluating lower doses of MHT and directly comparing transdermal and oral formulations. Such research should help define the population of women most likely to benefit from MHT without undue risk of adverse outcomes.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Cabral, Aléxia Alves, Vanessa Manso Torres und Janaína Henriques Sobrinho Ribeiro. „Indicações, riscos e benefícios da reposição de hormônios bioidênticos na menopausa: uma revisão narrativa“. Cadernos UniFOA 17, Nr. 48 (01.04.2022): 147–52. http://dx.doi.org/10.47385/cadunifoa.v17.n48.3592.

Der volle Inhalt der Quelle

Annotation:

RESUMOAtualmente, a terapia de reposição hormonal (TRH) na menopausa está indicada na presença de sintomas vasomotores e síndrome geniturinária da menopausa e para prevenção da perda de massa óssea e menopausa precoce. Após serem demonstrados riscos cardiovasculares e tromboembólicos em mulheres em uso da TRH, iniciaram-se novas buscas por alternativas de reposição hormonal. Essa revisão objetiva pontuar as indicações da TH para mulheres na menopausa e discutir sobre a atualização das novas tecnologias de TH, tratando-se dos hormônios bioidênticos (HB). Trata-se de uma revisão narrativa, realizada no intervalo de Outubro a Novembro de 2020, por meio do levantamento de evidências nos bancos de dados Google Acadêmico, PubMed® e Scielo. Apesar da controversa envolvida na prescrição de HB na literatura, é irrefutável sua importância novo método terapêutico pós-menopausa, que vem sendo alvo de discussões e detém emergente necessidade de novos ensaios clínicos bem delineados. Diante disso, nota-se que a eficácia e segurança dos HB ainda estão em estudo e que, dentre as evidências já existentes, mostram-se associados à redução de efeitos colaterais, em comparação às TRH convencionais, e apresentam boa resposta clínica para os sintomas da menopausa. ABSTRACTCurrently, menopausal hormone replacement therapy (HRT) is indicated in the presence of vasomotor symptoms and menopausal genitourinary syndrome and for preventing bone mass loss and early menopause. After cardiovascular and thromboembolic risks were demonstrated in women using HRT, new searches for hormone replacement alternatives began. This review aims to point out the indications of HRT for women in menopause and discuss the update of the new bioidentical hormone therapy (BHT). This is a narrative review, carried out from October to November 2020, by means of the survey of evidence in the Google Scholar, PubMed® and Scielo databases. Despite the controversy in literature involved in prescribing BHT, its importance as a new post-menopausal therapeutic method is irrefutable, which has been the subject of discussions and has an emerging need for new well-designed clinical trials. Therefore, it is noted that the efficacy and safety of BHT are still under study and that, among the existing evidence, they are associated with the reduction of side effects, compared to conventional HRT, and have a good clinical response to symptoms of menopause.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "Menopause Hormone therapy"

Antoine, Caroline. „Menopause, breast cancer and menopausal treatments“. Doctoral thesis, Universite Libre de Bruxelles, 2018. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/271843.

Der volle Inhalt der Quelle

Annotation:

RESUME Introduction: Le cancer du sein (CS) est le cancer le plus fréquent chez la femme. Le risque de CS est influencé par de nombreux facteurs. Le traitement hormonal de la ménopause (THM) est l’un d’entre eux. Le risque de CS associé au THM varie probablement en fonction de la population traitée, du type de traitement utilisé, de la durée du traitement et du moment où il est instauré par rapport au début de la ménopause. Il existe des alternatives au THM pour soulager les symptômes de la ménopause. Quelques traitements ont montré une certaine efficacité mais présentent des effets secondaires. D’autres traitements doivent faire l’objet d’études plus approfondies. Objectifs: 1) Contribuer à l’analyse de l’influence du THM sur le CS. 2) Contribuer à l’amélioration de la qualité de vie des patientes ayant eu un CS. Résultats: 1) Nous avons analysé l’évolution de l’incidence du CS et des ventes de THM en Belgique et montré une corrélation entre ces deux paramètres. Nous avons réalisé une revue systématique des études analysant l’association entre l’incidence du CS et l’utilisation de THM. Toutes présentaient des limitations et leur hétérogénéité les rendait difficilement comparables. Nous avons analysé l’évolution des ventes de THM en Europe et montré une diminution importante au cours de la dernière décennie dans l’ensemble des pays étudiés. Nous avons analysé l’évolution de l’incidence du CS et de l’utilisation des THM dans différents pays européens et n’avons pas trouvé d’association entre ces deux paramètres. Nous avons réalisé une revue systématique des études évaluant l’influence du THM sur les caractéristiques du CS et montré que les CS développés sous THM n’étaient pas de meilleur pronostic. 2) Nous avons réalisé deux revues systématiques sur la sécurité d’emploi des THM et des traitements non hormonaux de la ménopause chez les femmes ayant eu un CS. Nous avons montré que le CS représentait une contre-indication au THM et que peu de données existaient concernant les traitements alternatifs. Nous avons mené deux études concernant l’utilisation de traitements de la ménopause chez les femmes ayant eu un CS et montré qu’une proportion importante des femmes ayant eu un CS présentait des symptômes de la ménopause mais que peu d’entre elles utilisaient un traitement. Certains de ces traitements pouvaient potentiellement réduire l’efficacité de leur traitement contre le CS. Conclusions: 1) L’influence exacte du THM sur l’incidence du CS reste difficile à déterminer. D’autres facteurs interviennent également. Nous avons montré l’importance du temps lorsqu’on observe l’évolution de deux paramètres. 2) Les traitements sûrs et efficaces des symptômes de la ménopause chez les femmes ayant eu un CS sont limités. La qualité de vie des patientes ménopausées, ayant souffert d’un CS, peut cependant être nettement améliorée.
ABSTRACT Introduction: Breast cancer (BC) is the most common cancer in women. BC risk is influenced by many factors. Menopausal hormone therapy (MHT) is one of them. BC risk associated with MHT may vary depending on the treated population, the type of MHT used, the treatment duration and the delay between the beginning of the treatment and the onset of the menopause. There are alternatives to MHT for the treatment of menopausal symptoms. Some of them have shown some efficacy but have side-effects. Others need further research. Objectives: (1) To contribute to the analysis of the influence of MHT on BC; (2) to contribute to the improvement of the quality of life of BC patients. Results: (1) We analysed changes in BC incidence and MHT sales in Belgium and showed a correlation between these two parameters. We made a systematic review of studies analysing the association between BC incidence and MHT use. All the studies had limitations and were heterogeneous, making them difficult to compare. We analysed changes in MHT sales in Europe and showed an important decrease during the last decade in all the studied countries. We analysed changes in BC incidence and MHT sales in several European countries and found no association between these two parameters. We made a systematic review of studies assessing the influence of MHT on BC characteristics and showed that cases of BC developed under MHT did not have a better prognosis. (2) We made two systematic reviews on the safety of MHT and non-hormonal treatments in BC patients. We showed that BC was a contra-indication to MHT and that few data on alternative treatments were available. We conducted two studies on the use of treatments to alleviate menopausal symptoms in BC patients and showed that an important proportion of these women suffered menopausal symptoms but that few of them were using a treatment. Some of these treatments could reduce the efficacy of their BC treatment. Conclusions: (1) The exact influence of MHT on BC incidence is difficult to evaluate. Other factors are also involved. We showed that long follow-ups are needed when analysing time trends. (2) Efficient and safe treatments for menopausal symptoms in BC patients are limited. However, the quality of life of BC patients may be improved.
Doctorat en Sciences biomédicales et pharmaceutiques (Médecine)
info:eu-repo/semantics/nonPublished

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Homer, Natalie. „Erythocyte oxidative stress : focus on hormone replacement therapy“. Thesis, University of Strathclyde, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273852.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Rhoads, Misty Lynn. „Hormone replacement therapy : attitudes, knowledge, and usage by perimenopausal and postmenopausal women /“. View online, 2005. http://repository.eiu.edu/theses/docs/32211131275302.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Towne, Cheryl Luann Rush. „Older women's beliefs about hormone replacement therapy : a qualitative study /“. View online, 2000. http://repository.eiu.edu/theses/docs/32211130976791.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Fischer, Mary A. „Women’s Experiences of Discontinuing Hormone Therapy: A Dissertation“. eScholarship@UMMS, 2011. https://escholarship.umassmed.edu/gsn_diss/23.

Der volle Inhalt der Quelle

Annotation:

Although many women find relief from menopause through hormone therapy (HT), current guidelines recommend that HT be used only for short-term relief of symptoms. Women who attempt to stop HT often encounter troublesome recurrent symptoms leading to a diminished quality of life (QoL); 25% of women who discontinue eventually resume HT. Unfortunately, there is little information for women and their health care providers as to the best way to discontinue HT or how to prepare and guide women through this process. An in-depth description of women‘s experiences during HT discontinuation and the factors influencing recurrent symptoms, QoL and discontinuation outcome would provide knowledge to develop much needed counseling and support interventions. The purpose of this study was to explore women‘s experiences discontinuing hormone therapy for menopause. This Internet-based mixed-methods study used a dominant Qualitative Descriptive design with embedded quantitative QoL measurements. Participants completed the quantitative questionnaires online while open-ended questions were completed either online or by telephone. Interview data were analyzed through Qualitative Content Analysis; descriptive statistics were used to explore the quantitative measures. Participants were stratified by discontinuation status for comparison of variations in discontinuation experiences, QoL and influencing factors. Thirty-four women (20 stopped, 9 resumed, 4 tapering) were enrolled. One overarching theme--'a solitary journey'--emerged: although all women embarked on this journey, each woman traveled her own path. Two subthemes--'burden and interference' and 'appraising risk'--encompassed the symptom factors (severity, interference and sensitivity) that influenced women's experiences and the manner in which women evaluated their options. Other influencing factors included: readiness viii and reasons for stopping HT, beliefs about menopause and roles. QoL was strongly connected to symptoms for many but not all women. Information from health care providers was inconsistent; women desired more support from providers and other women. The rich description of women's experiences stopping HT highlights the need for providers to assess women's sensitivity to symptoms and readiness to discontinue to determine which women might benefit from more support. Greater health literacy would enhance women's understanding of HT risks. More research is needed on symptom clusters and interference and strategies for minimizing their impact.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Yeung, Wing-kwan Rosa. „Adjunctive effect on hormone replacement therapy on periodontal treatment responses in postmenopausal women“. Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B3765195X.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Ballard, Karen Dawn. „Women on the verge of HRT : factors influencing women's decisions about taking hormone replacement therapy“. Thesis, Royal Holloway, University of London, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.396150.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Yeung, Wing-kwan Rosa, und 楊穎筠. „Adjunctive effect on hormone replacement therapy on periodontal treatment responses in postmenopausal women“. Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B3765195X.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Sanders, Sharon Lea. „The effectiveness of hormone replacement therapy in the treatment of depressed mood and depressive disorders occurring during the climacteric /“. [St. Lucia, Qld.], 2002. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe16707.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Thompson, Jennifer Jo, Cheryl Ritenbaugh und Mark Nichter. „Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making“. BIOMED CENTRAL LTD, 2017. http://hdl.handle.net/10150/626039.

Der volle Inhalt der Quelle

Annotation:

Background: In recent years, compounded bioidentical hormone therapy (CBHT) has emerged as a popular alternative to manufactured, FDA approved hormone therapy (HT)-despite concerns within the medical community and the availability of new FDA approved "bioidentical" products. This study aims to characterize the motivations for using CBHT in a U.S. sample of ordinary midlife women. Methods: We analyze data collected from 21 current and former users of CBHT who participated in a larger qualitative study of menopausal decision-making among U.S. women. Interviews and focus groups were audio-recorded, transcribed verbatim, and analyzed thematically using an iterative inductive and deductive process. Results: Although women's individual motivations varied, two overarching themes emerged: "push motivations" that drove women away from conventional HT and from alternative therapies, and "pull motivations" that attracted women to CBHT. Push motivations focused on (1) fear and uncertainty about the safety of conventional HT, (2) an aversion to conjugated estrogens in particular, and (3) and overarching distrust of a medical system perceived as dismissive of their concerns and overly reliant on pharmaceuticals. Participants also voiced dissatisfaction with the effectiveness of herbal and soy supplements. Participants were attracted to CBHT because they perceive it to be (1) effective in managing menopausal symptoms, (2) safer than conventional HT, (3) tailored to their individual bodies and needs, and (4) accompanied by enhanced clinical care and attention. Conclusions: This study finds that women draw upon a range of "push" and "pull" motivations in their decision to use CBHT. Importantly, we find that women are not only seeking alternatives to conventional pharmaceuticals, but alternatives to conventional care where their menopausal experience is solicited, their treatment goals are heard, and they are engaged as agents in managing their own menopause. The significance of this finding goes beyond understanding why women choose CBHT. Women making menopause treatment decisions of all kinds would benefit from greater shared decision-making in the clinical context in which they are explicitly invited to share their experiences, priorities, and preferences. This would also provide an opportunity for clinicians to discuss the pros and cons of conventional HT, CBHT, and other approaches to managing menopause.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Bücher zum Thema "Menopause Hormone therapy"

Buckman, Rob. Todo lo que hay que saber sobre--: La menopausia y el tratamiento hormonal sustitutorio. Buenos Aires: Planeta, 2001.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Hawkins, Amy Lee. Replacing hormone replacements: Your bioidentical hormone solution. North Branch, MN: Sunrise River Press, 2011.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Clinic, Marie Stopes, Hrsg. Menopause & HRT. London: Ward Lock, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

HRT: Hormone replacement therapy. New York: DK Pub., 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Smith, Roger N. J. The menopause and hormone replacement therapy. 2. Aufl. London: Dunitz, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Obstetrics, Consultant, Senior Lecturer in Obstetrics und Juliet E. Compston MD FRCPath FRCP FMedSci. Hormone Replacement Therapy and the Menopause. Herausgegeben von Michael S. Marsh MD MRCOG. Abingdon, UK: Taylor & Francis, 1988. http://dx.doi.org/10.4324/9780203213735.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Smith, Roger. The menopause and hormone replacement therapy. London: Dunitz, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Genazzani, A. R. Hormone Replacement Therapy and Neurological Function. London: Informa Healthcare, 2003.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kleerekoper, Michael. Hormone replacement therapy and osteoporosis. London: Parthenon, 2003.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Royal College of Obstetricians and Gynaecologists. Problems with hormone replacement therapy (HRT). London: RCOG Press, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Buchteile zum Thema "Menopause Hormone therapy"

Kennard, Elizabeth A. „Hormone Replacement Therapy“. In Menopause, 139–54. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-246-3_9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Geraghty, Patricia. „Menopause Hormone Therapy“. In Each Woman’s Menopause: An Evidence Based Resource, 121–43. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-85484-3_6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Lambrinoudaki, Irene, und Eleni Armeni. „Menopause Hormone Therapy Customization“. In Pre-Menopause, Menopause and Beyond, 253–59. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-63540-8_22.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Quereda, Francisco. „Hormone Therapy (I): Estrogens, Progestogens, and Androgens“. In Menopause, 181–96. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59318-0_11.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Palacios, Santiago, und Mariella Lilue. „Hormone Therapy (II): Tibolone, The TSEC Concept“. In Menopause, 197–212. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59318-0_12.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Navarro-Pardo, Esperanza, Tomi S. Mikkola, Tommaso Simoncini, Marta Millán, María Dolores Juliá und Antonio Cano. „The Impact of Hormone Therapy on Health“. In Menopause, 225–47. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59318-0_14.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Paciuc, John. „Hormone Therapy in Menopause“. In Advances in Experimental Medicine and Biology, 89–120. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-38474-6_6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Sherif, Katherine. „FAQ: Definitions of Menopause and Biological Actions of Sex Steroids“. In Hormone Therapy, 3–15. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6268-2_1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Linn, Edward S., und Lara Weyl. „Hormone Replacement Therapy in Menopause“. In Ambulatory Gynecology, 231–45. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7641-6_15.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Hernández-Angeles, Claudio, und Camil Castelo-Branco. „The Impact of Hormone Therapy on the Clinical Symptoms of Menopause“. In Menopause, 213–23. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59318-0_13.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Menopause Hormone therapy"

Bunting, Haley A., Ryan T. Cassilly, Brian Jin, Christopher S. Ahmad, Louis U. Bigliani, William N. Levine und Thomas R. Gardner. „Effect of Hormone Therapy on Tensile Strain of the Macaque Inferior Glenohumeral Ligament“. In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53531.

Der volle Inhalt der Quelle

Annotation:

The effect of hormone treatment on the material properties of ligaments has been extensively studied for the anterior cruciate ligament (ACL). However, there have been few studies on the effects of hormones on the material properties of the shoulder. Shoulder ligaments contribute to overall shoulder stability, and a change in ligament properties could contribute to a change in overall shoulder laxity. Cynomolgus monkeys have served as nonhuman primate models in studies examining the effects of hormone replacement therapy on the cardiovascular system, as well as serving as a model for menopause, reproductive support structures, the knee joint and shoulder joint. The cynomolgus macaques are commonly used for studies involving hormone replacement therapy because they have 28-day menstrual cycles with very similar hormonal patterns to that of women. This study uses female cynomologus macaque (Macaca fascicularis) monkeys as an animal model of the human shoulder to determine if estrogen has an effect on the strain distribution of the inferior glenohumeral ligament (IGHL).

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Gardner, Thomas R., Ryan T. Cassilly, Brian Jin, Anuli N. Mkparu, Christoper S. Ahmad, Louis U. Bigliani und William N. Levine. „Effect of Estrogen on Viscoelastic Properties of the Anterior Pouch of the Macaque Animal Model of the Inferior Glenohumeral Ligament“. In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206835.

Der volle Inhalt der Quelle

Annotation:

The effect of hormone treatment on the material properties of ligaments has been extensively studied for the anterior cruciate ligament (ACL). However, there have been very few studies on the effects of hormones on the material properties of the shoulder. These shoulder ligaments contribute to overall shoulder stability, and a change in ligament properties could contribute to a change in overall shoulder laxity. This study uses female cynomologus macaque (Macaca fascicularis) monkeys as an animal model of the human shoulder to determine if estrogen has an effect on the viscoelastic properties of the anterior pouch of the inferior glenohumeral ligament (IGHL). Cynomolgus monkeys have served as nonhuman primate models in several studies, including monkey models of menopause, the effects of hormone replacement therapy on the cardiovascular system, reproductive support organs, and the knee joint. The cynomolgus macaques are commonly used for studies involving hormone replacement therapy because they have 28-day menstrual cycles with very similar hormonal patterns to that of women.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Vieira, Amanda Cristina de Souza, Antônio Pedro Oliveira de Vasconcelos, Jaqueline Maria Pinheiro de Araujo, Juliana Comin Müller, Larissa de Cassia Afonso Magalhães, Renato Duarte da Silva, Ricardo Baroni Vieira und Fabiana Candida de Queiroz Santos Anjos. „EPIDEMIOLOGICAL RELATIONSHIP BETWEEN HORMONE REPLACEMENT THERAPY AND BREAST CANCER“. In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2090.

Der volle Inhalt der Quelle

Annotation:

Objective: The aim of this study was to epidemiologically analyze the hormone replacement therapy (HRT) and the emergence of breast cancer. Methodology: This is an article review from the databases such as LILACS, SciELO, Bireme, and Medscape, utilizing the keywords: menopause, HRT, breast cancer and complications, employing the use of connectors when necessary. This review aims to elucidate what has been published in the last years about the usage of hormone therapy and the emergence of breast cancer since there are disagreements between the literature. Results: The analysis displayed positive effects during the usage of HRT, such as maintenance of bone density, prevention of fractures, and cardiovascular events in patients with no previous changes in this system, and also showed us a strong relationship between HRT and the incidence of breast cancer in menopausal women with a focus into the imposing time of use ratio. Meanwhile, this development risk of breast CA can be reduced in the long run with the withdrawal of the previously initiated therapy. The progesterone HRT has been shown to have lower risks in association with estrogen than when compared with the association of synthetic progestins and estrogen. Associations have similar results for oral and skin HRT. In patients using the postmenopausal hormone therapy, the risk of mortality from breast cancer was reduced in patients with exposure for a maximum of 5 years, more than 5–10 years, or more than 10 years. Conclusion: In view of the exposure, it is considered that the HRT is more beneficial than malefic to the life and health of women. Meanwhile, the risk of breast CA goes up while the HRT time stretches over the years. Thus, it is necessary to individually evaluate the benefits and risks to better identify the therapy that should be utilized.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Jang, J.-H., N. Arora, G. Hanley und J. Kwon. „P163 Hormone replacement therapy use after premature surgical menopause and impact on subsequent health services“. In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.224.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Sousa-Lima, Renata, Isabella Machado, Luiz-Francisco Freitas, Gilson Veloso und Angelica Rodrigues. „EP089/#784 Low use of hormone therapy in women with early menopause arising from treatment for cervical cancer“. In IGCS 2022 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-igcs.180.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Li, Tricia, Jiali Han und Chunyan He. „Abstract 1741: The association between menopause symptoms and risk of postmenopausal breast cancer among non-users of hormone therapy“. In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1741.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zhang, P., und J. G. Zein. „Menopausal Hormone Replacement Therapy and Risk of Asthma“. In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7089.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Pratt, Sheila Alhana, Valeria Sanabria, Ana Soskin, Aurora Rocio Rizzi und Marcos Cabrera. „ADENOID CYSTIC CARCINOMA OF THE BREAST“. In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1014.

Der volle Inhalt der Quelle

Annotation:

Introduction: Adenoid cystic adenoid carcinoma (ACC) of the breast is a rare variant that occurs in large series only in less than 1% of the patients. It has favorable prognosis and morphological resemblance to tumors originating in the salivary glands. Histopathological diagnosis is based on a mixture of proliferating glands, which correspond to the adenoid component and the replication of the basal membrane in the form of cylinders established by the pseudoglandular component. It usually occurs in adult women. Its form of clinical presentation is a painless breast nodule, located in the retroareolar region, without compromise of skin or nipple secretion, of small size and circumscribed limits. Treatment of ACC is not protocolized, although it is accepted that conservative surgery is applicable in most cases. Our goal is to publicize the clinical case of a patient treated in our service and to show some clinical and histopathological aspects of this same rare pathology. Case report: 63-year-old patient, with no history of cancer in the family, menarche at 16 years of age, three full births, 24 months of lactation, menopause at 46 years of age, no hormone replacement therapy. Hypertensive and diabetic, a right breast nodule was self-detected six months before; slow and painless growth that then fistulizes the skin and is accompanied by serohematic secretion of a gelatinous consistency. On physical examination, a 7 cm nodule is felt in lower quadrants, showing elastic consistency and poorly defined edges. No adenopathies in the armpits or neck. Sectional biopsy performed in another service. Pathological anatomy: differential diagnosis between Cystic Hypersecretory Carcinoma and Cystic Secretory Hyperplasia. With the diagnosis of ACC of the right breast, T2N0Mx stage IIa. Mammography: breasts type b, at the junction of lower quadrants of the right breast, dense delimited mass measuring 5x4 cm, no retraction or skin edema. BIRADS V. Ecograph: A mass located in H6 to 3 cm of the nipple with well delimited edges, with heterogeneous characteristics with liquid and solid areas of 5.71 cm x 4.06 cm. BIRADS V. Extensive resection and sentinel node biopsy is performed. Histopathological result revealed ACC G1 of 5.5 cm with no associated in situ carcinoma. No vascular plungers or perineural invasion are observed. Free surgical limits. pT3 Nx.Mx. Immunohistochemistry: RE-; RP-; HER2-;ki67 <14%. Our case showed a neoplastic proliferation consisting of two types of cavity formation; true glandular lights (adenoid component) and pseudo lumens that produce basal membrane material (cylinder component) with eosinophilic basal membrane material, the adenoid component with basophilic mucin and surrounded by myoepithelial cells. Three negative lymph nodes metastasis. Radiation therapy was decided as an adjuvant treatment.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Cordina-Duverger, Emilie, Thérèse Truong, Antoinette Anger, Claire Mulot, Patrick Arveux, Pierre Kerbrat, Florence Menegaux und Pascal Guenel. „Abstract 655: Menopausal hormone therapy and breast cancer risk: The CECILE Study“. In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-655.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Jordahl, Kristina M., David R. Doody, Yuzheng Zhang, Donghui Yan, Timothy W. Randolph, Lisa G. Johnson, Christopher I. Li et al. „Abstract 2772: Hormone replacement therapy and genome-wide DNA methylation among post-menopausal women“. In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2772.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Menopause Hormone therapy"

Rada, Maria Patricia, Alexandra Caseriu, Roxana Crainic und Stergios K. Doumouchtsis. A critical appraisal and systematic review of clinical practice guidelines on hormone replacement therapy for menopause: assessment using the Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Dezember 2022. http://dx.doi.org/10.37766/inplasy2022.12.0089.

Der volle Inhalt der Quelle

Annotation:

Review question / Objective: To assess the quality of clinical practice guidelines (CPC) on hormone replacement therapy for menopause using the AGREE II instrument and to provide a summary of recommendations. Information sources: Literature searches using MEDLINE, Embase, Scopus, Geneva Foundation for Medical Education and Research from inception to date will be searched. The search terms include guidelines / guidance / recommendation and hormone replacement therapy related keywords and MeSH terms. National and international organizations websites will be searched individually. Additional searches on the references of the primary included items may help identify any guidelines missed on the primary searches. In the case of more than one published guideline from the same national or international association, only the latest version of the guidelines will be included and evaluated. Any disagreements on inclusion criteria will be addressed through discussion and consensus meeting within the research team. Guidelines published in languages other than English will be considered on an individual basis. Guidelines must be publicly available on a website or in a peer-reviewed publication.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!